About Us
Hong Kong Verily Health Technology Group is a leading healthcare technology enterprise, established by Verily in collaboration with consortiums from Hong Kong and Singapore.
Adopting the Latest Research Technologies
The group is committed to applying innovative technologies in the healthcare field, particularly in the development and application of artificial intelligence, big data analytics, and advanced medical devices. Hong Kong Verily’s core mission is to improve the quality of healthcare services in Southeast Asia, Hong Kong, and China, enhance patient diagnosis and treatment efficiency, and promote transparency in health information as well as the realization of personalized treatment plans. Through technological advancement, Hong Kong Verily aims to deliver more efficient and precise health management solutions to these regions.
Our Mission
Hong Kong Verily Health Technology Group is dedicated to improving people's health through technological innovation. We believe that by leveraging cutting-edge technology, we can significantly enhance the efficiency and effectiveness of healthcare services, thereby improving the quality of life for users worldwide.
Our Technology
We continuously push for technological innovation in artificial intelligence, big data analytics, and medical devices. Hong Kong Verily has successfully developed a variety of high-end medical equipment and intelligent analytical tools, which are helping us improve disease prediction, personalized treatment plans, and health management systems.
Our Team
Hong Kong Verily brings together a team of industry-leading scientists, engineers, and medical experts. Our leadership team has extensive industry experience and a solid technical background, dedicated to driving the company's innovation and growth while ensuring our technology meets market needs and brings about real change.
Qualifications & Honors
Hong Kong Verily Health Technology Group has received numerous international and regional certifications and awards for its outstanding contributions to the medical technology field, primarily focusing on honors from Hong Kong, Macau, and overseas:
- ISO 13485 Medical Device Quality Management System Certification: An international certification that confirms the company’s adherence to quality standards in global medical device manufacturing and services.
- Hong Kong Innovation and Technology Award: Recognizes the company’s excellence in technology innovation.
- Macau Health Technology Contribution Award: Acknowledges the company’s influence in the development of health technology in Macau.
- Asia-Pacific Medical Technology Leader Award: Awarded in the Asia-Pacific region, recognizing the company’s leadership in the medical technology industry.
- Global Health Technology Innovation Award: An international award for the company’s innovations in global health technology.
- Best Medical Solutions Provider in Southeast Asia: Recognizes the outstanding performance of the company’s solutions in the Southeast Asian market.
- Hong Kong Outstanding Corporate Social Responsibility Award: Honors the company’s excellence in corporate social responsibility practices.
- International Medical Device Innovation Award: Recognizes advanced medical device technology developed by the company.
- Hong Kong Green and Health Technology Award: Rewards the company’s contributions to green technology and health promotion.
- Macau Science and Technology Cooperation Award: Recognizes the successful collaboration and scientific achievements with research institutions in Macau.
- Asian Medical Technology Innovation Achievement Award: Awarded in the Asian region for the company’s outstanding achievements in medical technology innovation.
R&D Investment
Partners
Collaborative Projects
Heart Health Monitoring Project(In partnership with Philips)
Developing an intelligent heart monitoring system called "Heart Moment."
Diabetes Management Innovation(In partnership with Medtronic)
Launching the "Diabetes Control Elite" management system.
Precision Oncology Treatment(In partnership with Roche)
Developing a precision treatment plan named "Tumor Shadowless."
Remote Patient Monitoring System(In partnership with GE Healthcare)
Launching the "Health Guardian" remote monitoring system.
Advanced Diagnostic Technology(In partnership with Siemens Healthineers)
Developing the "Diagnostic Pioneer" series of products.
Biopharmaceutical R&D(In partnership with Pfizer)
Conducting biopharmaceutical research targeting specific diseases.
Intelligent Surgical System(In partnership with Johnson & Johnson)
Launching the "Surgical Wizard" intelligent system.
Personalized Medical Data Platform(In partnership with Google Cloud)
Developing the "Personal Health" data platform.
Development History
2024
- April: Verily launched its first AI health analysis tool, combining intelligent health monitoring systems, leading the way in early screening for chronic diseases and personalized health management, receiving high praise in the industry.
- July: The group showcased its latest medical technology products at the Hong Kong Technology Expo, winning multiple industry innovation awards, further enhancing the company’s international influence.
- August: Verily Health Technology Group was officially established in Hong Kong, leveraging technology support from Verily in the U.S. and capital investment from a Singapore consortium, focusing on R&D innovation in AI health management, gene-targeted drugs, and stem cell applications.
- October: Verily partnered with several top hospitals worldwide to begin deploying an AI-based telemedicine platform, covering Asia, Europe, and North America, breaking geographical barriers to provide high-quality medical services to remote areas.
2023
- February: Verily signed a strategic cooperation agreement with the National University Hospital of Singapore to jointly develop an intelligent health management system, promoting its application in Southeast Asia, with rapid rollout of project results in multiple countries in the region.
- May: The group’s AI-driven health management platform successfully passed certification from China’s national health department and conducted pilot applications in top hospitals across 10 provinces and cities in China.
- August: With technical support from Verily, Verily successfully launched a new generation of telemedicine monitoring devices to improve long-term health management efficiency for chronic disease patients, winning the “International Medical Technology Innovation Award.”
- December: Verily reached a strategic cooperation agreement with MSD to jointly develop gene-targeted drugs for cancer patients, further expanding its business layout in the precision medicine field.
2022
- March: A Singapore consortium and Verily officially launched a joint project to advance health tech infrastructure in Southeast Asia, with the first batch of smart health devices successfully deployed in Singapore, Malaysia, Indonesia, and other countries.
- June: Verily partnered with Pfizer to jointly develop targeted drug treatment plans based on genomic data, with the first batch of drugs showing significant efficacy in laboratory trials, further promoting the development of precision medicine.
- September: The company received the “Southeast Asia Medical Technology Development Contribution Award,” recognizing its outstanding contributions to promoting smart medical and telemedicine devices, and playing a leading role in regional medical technology innovation.
- November: Verily’s stem cell wound repair project gained attention at the International Cell Therapy Conference, showing the immense potential of stem cells in regenerative medicine.
2021
- February: A Singapore consortium and Verily began close cooperation to promote the deployment of a big data medical platform in Southeast Asia, establishing a preliminary health data analysis network, laying a solid foundation for the future establishment of the group.
- May: The “International Standards for Safe Use of Smart Medical Devices,” drafted by Verily, received wide recognition from global medical institutions and was implemented in the Asia-Pacific and European regions, becoming an industry benchmark.
- July: Verily’s AI-driven chronic disease management system successfully passed multiple international medical standard certifications, widely applied in the management of chronic diseases such as heart disease and diabetes, achieving good clinical results.
- November: The company signed a cooperation agreement with Osaka University in Japan to jointly develop gene-targeted drugs and stem cell regeneration therapies, providing more advanced personalized treatment options for Asian patients.
2020
- January: A Singapore consortium and Verily engaged in strategic discussions to explore how to drive global health tech innovation through technological cooperation and capital support, initially determining a resource allocation strategy in the Chinese and Southeast Asian markets.
- March: Both parties launched several joint research projects focused on the application of artificial intelligence in health management, telemedicine, and gene therapy, aiming to promote the global spread of precision medicine.
- June: Verily’s first smart health monitoring device entered the clinical testing phase, combining Verily’s advanced sensing technology to achieve round-the-clock health data monitoring.
- September: The Singapore consortium increased its investment in AI and gene-targeted drugs to advance Verily’s technological development, initially forming the framework for the company’s health tech ecosystem.
- December: The Verily team completed the core technology development for the smart health monitoring platform, laying the foundation for the subsequent formal establishment of the company and large-scale product promotion.